 Ultragenyx Pharmaceutical Inc NASDAQ: RARE has announced longer-term data from the Glycogen Storage Disease Type Ia GSDIa and Ornithine Transcarbamylase OTC Deficiency Phase 12 studies. Data were presented at the American Society of Gene Cell Therapy ASGCT 24th Annual Meeting. 